Search for other papers by Parmita Kar in
Google Scholar
PubMed
Search for other papers by Ravinder Goswami in
Google Scholar
PubMed
Basal ganglia calcification (BGC) is a common complication in hypoparathyroid patients, linked to hyperphosphatemia and altered vitamin-D and calcium homeostasis following conventional therapy. The pathogenesis of BGC in hypoparathyroidism is not clear. Recently, we developed an ex vivo model of BGC using rat-striatal cell culture in 10.0 mmol/L of β-glycerophosphate (31.8 mg/dL phosphate). However, the effect of 1,25(OH)2 D, calcium, and milder phosphate excess on BGC in hypoparathyroidism is not known. This study describes two modified ex vivo models investigating pathogenesis of BGC in ‘drug-naïve’ and ‘conventionally treated’ hypoparathyroid state. The first modification involved striatal cells cultured in low concentration 1,25(OH)2D (16.0 pg/mL), ionized calcium(0.99 mmol/L), hPTH(1-34) (6.0 pg/mL), and 2.68 mmol/L (8.3 mg/dL) of phosphate akin to ‘drug-naïve’ state for 24 days. In second modification, striatal cells were exposed to 46.0 pg/mL of 1,25(OH)2D, normal ionized calcium of 1.17 mmol/L, and 2.20 mmol/L (6.8 mg/dL) of phosphate akin to ‘conventionally treated’ state. Striatal cell culture under ‘drug-naïve’ state showed that even 16.0 pg/mL of 1,25(OH)2D enhanced the calcification. In ‘conventionally treated’ model, striatal cell calcification was enhanced in 54% cases over ‘drug-naïve’ state. Calcification in ‘conventionally treated’ state further increased on increasing phosphate to 8.3 mg/dL, suggesting importance of phosphatemic control in hypoparathyroid patients. Striatal cells in ‘drug-naïve’ state showed increased mRNA expression of pro-osteogenic Wnt3a, Cd133,Vglut-1-neuronal phosphate-transporters, calcium-ion channel-Trvp2,Alp, and Collagen-1α and decreased expression of Ca-II. These models suggest that in ‘drug-naïve’ state, 1,25(OH)2D along with moderately elevated phosphate increases the expression of pro-osteogenic molecules to induce BGC. Although normalization of calcium in ‘conventionally treated’ state increased the expression of Opg, Osterix, Alp, and Cav2, calcification increased only in a subset, akin to variation in progression of BGC in hypoparathyroid patients on conventional therapy.
Search for other papers by Jin Bai in
Google Scholar
PubMed
Search for other papers by Thomas J Lechuga in
Google Scholar
PubMed
Search for other papers by Joshua Makhoul in
Google Scholar
PubMed
Search for other papers by Hao Yan in
Google Scholar
PubMed
Search for other papers by Carol Major in
Google Scholar
PubMed
Search for other papers by Afshan Hameed in
Google Scholar
PubMed
Search for other papers by Dong-bao Chen in
Google Scholar
PubMed
Elevated endogenous estrogens stimulate human uterine artery endothelial cell (hUAEC) hydrogen sulfide (H2S) production by selectively upregulating the expression of H2S synthesizing enzyme cystathionine β-synthase (CBS), but the underlying mechanisms are underdetermined. We hypothesized that CBS transcription mediates estrogen-stimulated pregnancy-dependent hUAEC H2S production. Estradiol-17β (E2β) stimulated CBS but not cystathionine γ-lyase (CSE) expression in pregnant human uterine artery ex vivo, which was attenuated by the estrogen receptor (ER) antagonist ICI 182,780. E2β stimulated CBS mRNA/protein and H2S production in primary hUAEC from nonpregnant and pregnant women, but with greater responses in pregnant state; all were blocked by ICI 182,780. Human CBS promoter contains multiple estrogen-responsive elements (EREs), including one ERE preferentially binding ERα (αERE) and three EREs preferentially binding ERβ (βERE), and one full ERE (α/βERE) and one half ERE (½α/βERE) binding both ERα and ERβ. Luciferase assays using reporter genes driven by human CBS promoter with a series of 5′-deletions identified the α/βEREs binding both ERα and ERβ (α/βERE and ½α/βERE) to be important for baseline and E2β-stimulated CBS promoter activation. E2β stimulated ERα/ERβ heterodimerization by recruiting ERα to α/βEREs and βERE, and ERβ to βERE, α/βEREs, and αERE. ERα or ERβ agonist alone trans-activated CBS promoter, stimulated CBS mRNA/protein and H2S production to levels comparable to that of E2β-stimulated, while ERα or ERβ antagonist alone abrogated E2β-stimulated responses. E2β did not change human CSE promoter activity and CSE mRNA/protein in hUAEC. Altogether, estrogen-stimulated pregnancy-dependent hUAEC H2S production occurs by selectively upregulating CBS expression via ERα/ERβ-directed gene transcription.
Department of Medicine, University of Helsinki and Helsinki University Hospital, Haartmaninkatu, Helsinki, Finland
Search for other papers by Selina Mäkinen in
Google Scholar
PubMed
Department of Medicine, University of Helsinki and Helsinki University Hospital, Haartmaninkatu, Helsinki, Finland
Search for other papers by Neeta Datta in
Google Scholar
PubMed
Search for other papers by Savithri Rangarajan in
Google Scholar
PubMed
Department of Medicine, University of Helsinki and Helsinki University Hospital, Haartmaninkatu, Helsinki, Finland
Search for other papers by Yen H Nguyen in
Google Scholar
PubMed
Department of Anatomy, Faculty of Medicine, Haartmaninkatu, University of Helsinki, Helsinki, Finland
Search for other papers by Vesa M Olkkonen in
Google Scholar
PubMed
Turku PET Centre, Turku University Hospital, Kiinamyllynkatu, Turku, Finland
Search for other papers by Aino Latva-Rasku in
Google Scholar
PubMed
Turku PET Centre, Turku University Hospital, Kiinamyllynkatu, Turku, Finland
Search for other papers by Pirjo Nuutila in
Google Scholar
PubMed
Search for other papers by Markku Laakso in
Google Scholar
PubMed
Department of Medicine, University of Helsinki and Helsinki University Hospital, Haartmaninkatu, Helsinki, Finland
Search for other papers by Heikki A Koistinen in
Google Scholar
PubMed
Finnish-specific gene variant p.P50T/AKT2 (minor allele frequency (MAF) = 1.1%) is associated with insulin resistance and increased predisposition to type 2 diabetes. Here, we have investigated in vitro the impact of the gene variant on glucose metabolism and intracellular signalling in human primary skeletal muscle cells, which were established from 14 male p.P50T/AKT2 variant carriers and 14 controls. Insulin-stimulated glucose uptake and glucose incorporation into glycogen were detected with 2-[1,2-3H]-deoxy-D-glucose and D-[14C]-glucose, respectively, and the rate of glycolysis was measured with a Seahorse XFe96 analyzer. Insulin signalling was investigated with Western blotting. The binding of variant and control AKT2-PH domains to phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P3) was assayed using PIP StripsTM Membranes. Protein tyrosine kinase and serine-threonine kinase assays were performed using the PamGene® kinome profiling system. Insulin-stimulated glucose uptake and glycogen synthesis in myotubes in vitro were not significantly affected by the genotype. However, the insulin-stimulated glycolytic rate was impaired in variant myotubes. Western blot analysis showed that insulin-stimulated phosphorylation of AKT-Thr308, AS160-Thr642 and GSK3β-Ser9 was reduced in variant myotubes compared to controls. The binding of variant AKT2-PH domain to PI(3,4,5)P3 was reduced as compared to the control protein. PamGene® kinome profiling revealed multiple differentially phosphorylated kinase substrates, e.g. calmodulin, between the genotypes. Further in silico upstream kinase analysis predicted a large-scale impairment in activities of kinases participating, for example, in intracellular signal transduction, protein translation and cell cycle events. In conclusion, myotubes from p.P50T/AKT2 variant carriers show multiple signalling alterations which may contribute to predisposition to insulin resistance and T2D in the carriers of this signalling variant.
Search for other papers by Xiaopan Yang in
Google Scholar
PubMed
Search for other papers by Xiaojing Fan in
Google Scholar
PubMed
Search for other papers by Jiangyue Feng in
Google Scholar
PubMed
Search for other papers by Tinghui Fan in
Google Scholar
PubMed
Institute of Physical Science and Information Technology, Anhui University, Hefei, China
Search for other papers by Jingfei Li in
Google Scholar
PubMed
Search for other papers by Linfei Huang in
Google Scholar
PubMed
Search for other papers by Luming Wan in
Google Scholar
PubMed
Search for other papers by Huan Yang in
Google Scholar
PubMed
Search for other papers by Huilong Li in
Google Scholar
PubMed
Search for other papers by Jing Gong in
Google Scholar
PubMed
Search for other papers by Yanhong Zhang in
Google Scholar
PubMed
Search for other papers by Qi Gao in
Google Scholar
PubMed
Search for other papers by Fei Zheng in
Google Scholar
PubMed
Search for other papers by Lei Xu in
Google Scholar
PubMed
Search for other papers by Haotian Lin in
Google Scholar
PubMed
Department of Laboratory, General Hospital of Armed Police Forces, Anhui Medical University, Hefei, China
Search for other papers by Dandan Zhang in
Google Scholar
PubMed
Department of Laboratory, General Hospital of Armed Police Forces, Anhui Medical University, Hefei, China
Search for other papers by Hongbin Song in
Google Scholar
PubMed
Department of Laboratory, General Hospital of Armed Police Forces, Anhui Medical University, Hefei, China
Search for other papers by Yufei Wang in
Google Scholar
PubMed
Department of Laboratory, General Hospital of Armed Police Forces, Anhui Medical University, Hefei, China
Search for other papers by Xueping Ma in
Google Scholar
PubMed
Search for other papers by Zhiwei Sun in
Google Scholar
PubMed
Search for other papers by Cheng Cao in
Google Scholar
PubMed
Department of Laboratory, General Hospital of Armed Police Forces, Anhui Medical University, Hefei, China
Search for other papers by Xiaoli Yang in
Google Scholar
PubMed
Search for other papers by Hui Zhong in
Google Scholar
PubMed
Department of Endocrinology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
Search for other papers by Yi Fang in
Google Scholar
PubMed
Search for other papers by Congwen Wei in
Google Scholar
PubMed
Golgi protein 73 (GP73), also called Golgi membrane protein 1 (GOLM1), is a resident Golgi type II transmembrane protein and is considered as a serum marker for the detection of a variety of cancers. A recent work revealed the role of the secreted GP73 in stimulating liver glucose production and systemic glucose homeostasis. Since exaggerated hepatic glucose production plays a key role in the pathogenesis of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), GP73 may thus represent a potential therapeutic target for treating diabetic patients with pathologically elevated levels. Here, in this study, we found that the circulating GP73 levels were significantly elevated in T2DM and positively correlated with hemoglobin A1c. Notably, the aberrantly upregulated GP73 levels were indispensable for the enhanced protein kinase A signaling pathway associated with diabetes. In diet-induced obese mouse model, GP73 siRNA primarily targeting liver tissue was potently effective in alleviating abnormal glucose metabolism. Ablation of GP73 from whole animals also exerted a profound glucose-lowering effect. Importantly, neutralizing circulating GP73 improved glucose metabolism in streptozotocin (STZ) and high-fat diet/STZ-induced diabetic mice. We thus concluded that GP73 was a feasible therapeutic target for the treatment of diabetes.
Search for other papers by Belinda J Petri in
Google Scholar
PubMed
University of Louisville Center for Integrative Environmental Health Sciences (CIEHS), Louisvillle, Kentucky, USA
Search for other papers by Carolyn M Klinge in
Google Scholar
PubMed
Epitranscriptomic modification of RNA regulates human development, health, and disease. The true diversity of the transcriptome in breast cancer including chemical modification of transcribed RNA (epitranscriptomics) is not well understood due to limitations of technology and bioinformatic analysis. N-6-methyladenosine (m6A) is the most abundant epitranscriptomic modification of mRNA and regulates splicing, stability, translation, and intracellular localization of transcripts depending on m6A association with reader RNA-binding proteins. m6A methylation is catalyzed by the METTL3 complex and removed by specific m6A demethylase ALKBH5, with the role of FTO as an ‘eraser’ uncertain. In this review, we provide an overview of epitranscriptomics related to mRNA and focus on m6A in mRNA and its detection. We summarize current knowledge on altered levels of writers, readers, and erasers of m6A and their roles in breast cancer and their association with prognosis. We summarize studies identifying m6A peaks and sites in genes in breast cancer cells.
Search for other papers by Michela Zamboni in
Google Scholar
PubMed
Search for other papers by Georgios Strimpakos in
Google Scholar
PubMed
Search for other papers by Eleonora Poggiogalle in
Google Scholar
PubMed
Search for other papers by Lorenzo M Donini in
Google Scholar
PubMed
Search for other papers by Donato Civitareale in
Google Scholar
PubMed
Obesity affects thyroid gland function. Hypothyroidism, thyroid nodules, goiter, and thyroid cancer are more frequent in patients with higher BMI values. Although these data are supported by many clinical and epidemiological studies, our knowledge is very scarce at the molecular level. In this study, we present the first experimental evidence that adipocyte signaling downregulates the expression of thyroid-specific transcription factor 2 (TTF-2/FoxE1). It plays a crucial role in thyroid development and thyroid homeostasis and it is strictly connected to thyroid cancer as well. We provide in vivo and in vitro evidence that inhibition of TTF-2/FoxE1 gene expression is mediated by adipocyte signaling.
CIBB – Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal
MIA – Multidisciplinary Institute of Ageing, University of Coimbra, Coimbra, Portugal
Search for other papers by Sara Carmo-Silva in
Google Scholar
PubMed
CIBB – Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal
Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
Search for other papers by Marisa Ferreira-Marques in
Google Scholar
PubMed
ABC-RI, Algarve Biomedical Center Research Institute, Faro, Portugal
Faculdade de Medicina e Ciências Biomédicas, Universidade do Algarve, Faro, Portugal
Search for other papers by Clévio Nóbrega in
Google Scholar
PubMed
Search for other papers by Mariana Botelho in
Google Scholar
PubMed
CIBB – Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal
Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
Search for other papers by Daniela Costa in
Google Scholar
PubMed
CIBB – Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal
MIA – Multidisciplinary Institute of Ageing, University of Coimbra, Coimbra, Portugal
Search for other papers by Célia A Aveleira in
Google Scholar
PubMed
Search for other papers by Stefan M Pulst in
Google Scholar
PubMed
CIBB – Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal
Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
Search for other papers by Luís Pereira de Almeida in
Google Scholar
PubMed
CIBB – Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal
Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
Search for other papers by Claudia Cavadas in
Google Scholar
PubMed
ATXN2 gene, encoding for ataxin-2, is located in a trait locus for obesity. Atxn2 knockout (KO) mice are obese and insulin resistant; however, the cause for this phenotype is still unknown. Moreover, several findings suggest ataxin-2 as a metabolic regulator, but the role of this protein in the hypothalamus was never studied before. The aim of this work was to understand if ataxin-2 modulation in the hypothalamus could play a role in metabolic regulation. Ataxin-2 was overexpressed/re-established in the hypothalamus of C57Bl6/Atxn2 KO mice fed either a chow or a high-fat diet (HFD). This delivery was achieved through stereotaxic injection of lentiviral vectors encoding for ataxin-2. We show, for the first time, that HFD decreases ataxin-2 levels in mouse hypothalamus and liver. Specific hypothalamic ataxin-2 overexpression prevents HFD-induced obesity and insulin resistance. Ataxin-2 re-establishment in Atxn2 KO mice improved metabolic dysfunction without changing body weight. Furthermore, we observed altered clock gene expression in Atxn2 KO that might be causative of metabolic dysfunction. Interestingly, ataxin-2 hypothalamic re-establishment rescued these circadian alterations. Thus, ataxin-2 in the hypothalamus is a determinant for weight, insulin sensitivity and clock gene expression. Ataxin-2’s potential role in the circadian clock, through the regulation of clock genes, might be a relevant mechanism to regulate metabolism. Overall, this work shows hypothalamic ataxin-2 as a new player in metabolism regulation, which might contribute to the development of new strategies for metabolic disorders.
Search for other papers by Tijana Mitić in
Google Scholar
PubMed
Leading a research group as an early career researcher (ECR) in academia presents many challenges. First, it imposes many additional pressures on individuals, causing fear of missing out on a great opportunity that could advance your career. Together, the unsettling nature of short-term or temporary contracts, lack of guidance and the imposter syndrome can trigger a crisis in future leadership. Most leadership positions at universities are held by senior colleagues. ECRs have modest input in decision-making, due to a requirement for specific leadership training and experience with oversight that precedes suitable decision-making. The turbulence of the unprecedented world COVID-19 crisis has been felt disproportionally by many researchers, intensely by those with caring responsibilities. In the current academic climate, navigating either between your postdoctoral or fellowship project, leading others, taking strategic project directions, mentoring or networking may feel like too much. This editorial expresses views on the current state of the matter in academia with suggestions for helpful strategies to employ to meet research endpoints. It also addresses some challenges that new principal investigators and academic leaders may face due to external or institutional change, and provides some tangible advice with action points.
Search for other papers by Luca Clemente in
Google Scholar
PubMed
Department of Pediatrics, University of Wisconsin, School of Medicine and Public Health, Madison, Wisconsin, USA
Search for other papers by Ian M Bird in
Google Scholar
PubMed
The epidermal growth factor receptor (EGFR) is expressed robustly in the placenta, and critical processes of pregnancy such as placental growth and trophoblast fusion are dependent on EGFR function. However, the role that aberrant EGFR signaling might play in the etiology and/or maintenance of preeclampsia (PE) remains largely unexplored. Recently, we have shown that overexpression of EGFR in cultured uterine artery endothelial cells (UAEC), which express little endogenous EGFR, remaps responsiveness away from vascular endothelial growth factor receptor (VEGFR) signaling and toward EGFR, suggesting that endothelial EGFR expression may be kept low to preserve VEGFR control of angiogenesis. Here we will consider the evidence for the possibility that the endothelial dysfunction observed in PE might in some cases result from elevation of endothelial EGFR. During pregnancy, trophoblasts are known to synthesize large amounts of EGFR protein, and the placenta regularly releases syncytiotrophoblast-derived exosomes and microparticles into the maternal circulation. Although there are no reports of elevated EGFR gene expression in preeclamptic endothelial cells, the ongoing shedding of placental vesicles into the vascular system raises the possibility that EGFR-rich vesicles might fuse with endothelium, thereby contributing to the symptoms of PE by interrupting angiogenesis and blocking pregnancy-adapted vasodilatory function.
